GriffinSecurities Provides Updated Report on Unilife
Unilife Corporation (“Unilife” or the “Company”) (NASDAQ: UNIS; ASX: UNS) today advised for the interest of its Australian shareholders that U.S. investment banking firm Griffin Securities Inc has released an update of their independent research coverage on the Company.
Griffin Securities is a New-York City based research-driven investment banking firm providing corporate finance, merger and acquisitions, brokerage, and investment opportunities for institutional, corporate, and private clients. It initiated research coverage on Unilife in August 2009. Griffin Securities has advised Unilife that the report has been circulated to U.S. news wire services, its proprietary database, shareholders and peer groups, as well as published on its website: www.griffinsecurities.com/pdf/company-reports/Griffin_UNIS_Research_Update_10Mar11.pdf.
The report has been authored by analyst Keith Markey, PhD, Griffin Securities’ Scientific Director. He has been an equities analyst for more than 20 years, specializing in the biotechnology, pharmaceutical, and medical device sectors. Much of his career has been with Value Line, Inc., where he held various managerial positions in the Research Department for the world’s leading investment advisory newsletter, the Value Line Investment Survey. He was responsible for initiating coverage of stocks in all industries and created Value Line Select, a premium advisory publication. Keith began his career as a biochemist, working in the fields of endocrinology and neuroscience at New York University Medical School and Cornell Medical College. His research, which resulted in more than 30 scientific publications, contributed to our understanding of regulatory biochemistry and stem cell plasticity. Keith has lectured on scientific and financial subjects, and is a contributing editor to HUM-MOLGEN, a news service for the scientific research community. He is also a member of the New York Academy of Sciences and the National Association of Science Writers. Keith earned a Ph.D. in Neurochemistry from the University of
Connecticutand an M.B.A. in Finance from the Leonard N. Stern School of Business at New York University.
Download this document
